Latest R&D Spending Benchmark Study Puts Cancer Drug Costs At $648M
Executive Summary
Estimate in JAMA paper is significantly lower than often-cited $2.6bn in research and development costs projected in a 2014 study by Tufts Center for the Study of Drug Development.
You may also be interested in...
FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development
US FDA Commissioner notes that combined-phase clinical trials could be expanded beyond oncology as one way of reducing drug development costs.
Why Is Drug Pricing Higher In US? Study Takes Aim At R&D Argument
Amgen, Biogen, Pfizer and Teva generated more than twice their global R&D budgets with higher pricing in the US compared to Western Europe and Canada, researchers at Memorial Sloan Kettering found.
Cost Of New Drug Development Pushed To $2.6 Bil. By High Failure Rate – Study
The Tufts Centers for the Study of Drug Development updates its often-quoted drug development cost benchmark in a study released Nov. 18.